Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer?

Karen Kelly, Jr P.A. Bunn

Research output: Contribution to journalArticle

71 Scopus citations

Abstract

Brain metastases from non-small cell lung cancer develop in approximately one-third of patients. If not treated, neurological deterioration occurs quickly. Treatment with whole brain irradiation is advisable to palliate symptoms but despite this treatment, survival remains poor at 3-6 months. Recently, aggressive approaches with surgical resection and stereotactic radiosurgery have dramatically improved the control of brain metastases resulting in a meaningful survival advantage for a subset of eligible patients. New evidence also suggests a possible role for chemotherapy in the treatment of brain metastases. With several options now available to treat brain metastases proper patient selection is needed. This article will stratify patients with brain metastases and discuss the treatment modalities for each category. Copyright (C) 1998 Elsevier Science Ireland Ltd.

Original languageEnglish (US)
Pages (from-to)85-91
Number of pages7
JournalLung Cancer
Volume20
Issue number2
DOIs
StatePublished - 1998
Externally publishedYes

Keywords

  • Brain metastases
  • Non-small cell lung cancer
  • Treatment

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer?'. Together they form a unique fingerprint.

  • Cite this